Source link : https://yourblogdomain.com/2025/11/24/highly-anticipated-alzheimers-trials-yield-disappointing-results-for-glp-1-drug/
Source link : https://newshealth.biz/health-news/highly-anticipated-alzheimers-trials-yield-disappointing-results-for-glp-1-drug/ (MedPage Today) — The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer’s disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company shared topline results from the 2-year… Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/118689 Author : Publish date : 2025-11-24 22:02:00 Copyright for syndicated content […]
—-
Author : yourblogdomain
Publish date : 2025-11-24 22:59:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
Categories